Cargando…
A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2(+) breast cancer
Human epidermal growth factor receptor 2 (HER2)-targeted vaccines are under development, but have so far demonstrated only modest clinical efficacy. Additionally, there has been a lack of adequate safety assessment in large-scale prospective clinical trials. Therefore, we performed a meta-analysis o...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338114/ https://www.ncbi.nlm.nih.gov/pubmed/30679903 http://dx.doi.org/10.2147/DDDT.S188925 |